Incretin-based Therapy in Late Preclinical Type 1 Diabetes
Status:
Unknown status
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
The objective of the trial is to study whether daily treatment with liraglutide improves
endogenous insulin secretion, postpones progression to overt Type 1 diabetes, and is
tolerable and safe in subjects aged 10-30 years, who are positive for multiple islet
autoantibodies and have dysglycemia.
Phase:
Phase 2
Details
Lead Sponsor:
University of Oulu
Collaborators:
Oulu University Hospital Skane University Hospital Tampere University Hospital Turku University Hospital